Format

Send to

Choose Destination
See comment in PubMed Commons below
J Infect Dis. 2013 Jul;208(1):67-74. doi: 10.1093/infdis/jit127. Epub 2013 Mar 28.

Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus.

Author information

1
Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave, Detroit, MI 48201, USA.

Abstract

BACKGROUND:

 We used 2 in vitro experimental systems to compare phenotypic and genotypic changes that accompany selection of mutants of methicillin-resistant Staphylococcus aureus (MRSA) strain JH1 with low-level vancomycin resistance similar to the type found in vancomycin-intermediate S. aureus (VISA).

METHODS:

 The previously described MRSA strain JH1 and its vancomycin-intermediate mutant derivative JH2, both of which were recovered from a patient undergoing vancomycin chemotherapy, were used in this study. Mutants of JH1 were selected in vitro by means of a pharmacokinetic/pharmacodynamic (PK/PD) model of simulated endocardial vegetations (SEVs) and by exposure to vancomycin in laboratory growth medium. Phenotypic abnormalities of JH1 mutants generated by each in vitro experimental system were compared to those of JH2, and whole genomes of 2 in vitro JH1 mutants were sequenced to identify mutations that may be associated with an increased vancomycin minimum inhibitory concentration.

RESULTS:

 JH1R1 was selected from the PK/PD model, and JH1R2 was selected in laboratory growth medium. Both mutants displayed reduced vancomycin and daptomycin susceptibility and phenotypic alterations (eg, thicker cell walls and abnormal autolysis) that are typical of in vivo VISA mutants. Genome sequencing of JH1R1 identified point mutations in 4 genes, all of which were different from the mutations described in JH2, including 1 mutation in yycG, a component of the WalKR sensory regulatory system. Sequencing of the JH1R2 genome identified mutations in 7 genes, including 2 in rpoB.

CONCLUSION:

 Our findings indicate that JH1 is able to develop VISA-type resistance through several alternative genetic pathways.

KEYWORDS:

JH1; PK/PD model; VISA; cell wall thickness; genetic alterations; genome sequencing; pharmacokinetics/pharmacodynamics; phenotypic alteration; vancomycin resistance

PMID:
23539745
PMCID:
PMC3666135
DOI:
10.1093/infdis/jit127
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center